Amgen must face CareFirst's US claims over Enbrel, judge rules
MLex Summary: Amgen must face US antitrust claims from CareFirst accusing it of unlawfully delaying competition for its drug Enbrel, a federal judge ruled in an order denying dismissal. District Judge...To view the full article, register now.
Already a subscriber? Click here to view full article